Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Rong Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5170-6474; OpenAlex author ID A5100346447, A5112815806. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 0, last author 35)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 4 papers, 1 trial · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 6 papers · 2022: 7 papers · 2023: 8 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 41

  1. Metabolic syndrome worsens perioperative and oncological outcomes in patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter propensit… Last author DOI 10.1016/j.hbpd.2026.06.001↗
  2. New-onset diabetes worsens prognosis of patients with pancreatic ductal adenocarcinoma after R0 resection: A multicenter study. Last author DOI 10.1016/j.hbpd.2025.04.008↗
  3. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  4. Recognizing significance of propensity score matching and clinical practice in evaluating oncological survivals of pancreatic cancer. Last author DOI 10.21037/hbsn-24-615↗
  5. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  6. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  7. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. Last author DOI 10.1002/cam4.5871↗
  8. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center. Last author DOI 10.1016/j.hbpd.2022.09.006↗
  9. Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hbpd.2022.09.009↗
  10. Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study. Last author DOI 10.1097/js9.0000000000000296↗
  11. DCLRE1B promotes tumor progression and predicts immunotherapy response through METTL3-mediated m6A modification in pancreatic cancer. Last author DOI 10.1186/s12885-023-11524-8↗
  12. 18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal adenocarcinoma before surgery. Last author DOI 10.1186/s13550-023-00985-4↗
  13. Hypoxia-induced Long Non-coding RNA LSAMP-AS1 Regulates ceRNA Network to Predict Prognosis for Pancreatic Cancer. Last author DOI 10.2174/1386207326666230314112238↗
  14. Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis. Last author DOI 10.1007/s00280-021-04364-5↗
  15. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Last author DOI 10.1007/s00423-021-02321-7↗
  16. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduod… Last author DOI 10.1016/j.ijsu.2022.106891↗
  17. Molecular subtyping based on TRP family and prognostic assessment for TRP-associated lncRNAs in pancreatic adenocarcinoma. Last author DOI 10.1186/s12876-022-02552-y↗
  18. Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer. Last author DOI 10.3389/fimmu.2022.1052768↗
  19. Analysis of Pyroptosis-Related Signature for Predicting Prognosis and Tumor Immune Microenvironment in Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.770005↗
  20. Lactate Dehydrogenase B Is Required for Pancreatic Cancer Cell Immortalization Through Activation of Telomerase Activity. Co-author DOI 10.3389/fonc.2022.821620↗
  21. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic… Last author DOI 10.1080/21655979.2021.1992331↗
  22. Comment On "Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?" Last author DOI 10.1097/sla.0000000000004410↗
  23. Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma. Last author DOI 10.1111/jcmm.16573↗
  24. Methylation patterns partition pancreatic cancer into distinct prognostic subtypes. Last author DOI 10.2217/fon-2020-0804↗
  25. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy. Last author DOI 10.2217/fon-2021-0495↗
  26. Corrigendum: Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.817747↗
  27. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. Last author DOI 10.12998/wjcc.v8.i13.2778↗
  28. A novel epigenetic signature for predicting the prognosis of pancreatic ductal adenocarcinoma Last author DOI 10.21203/rs.3.rs-27415/v1↗
  29. Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2020.01378↗
  30. GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway. Last author DOI 10.1155/2019/9474273↗
  31. miR-125a induces apoptosis, metabolism disorder and migrationimpairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission. Last author DOI 10.3892/ijo.2018.4380↗
  32. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Co-author DOI 10.18632/oncotarget.21359↗
  33. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. Last author DOI 10.1007/s00280-016-3178-4↗
  34. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s10620-015-3931-2↗
  35. Clinical Significance of Preoperative CD8+ Central Memory T Cells for Operable Pancreatic Adenocarcinoma. Last author DOI 10.1159/000440681↗
  36. [Preoperative neutrophil-lymphocyte ratio as an independent prognostic predictor for pancreatic cancer]. Last author PMID 26710955↗
  37. Plasma ferritin levels, HFE polymorphisms, and risk of pancreatic cancer among Chinese Han population. Last author DOI 10.1007/s13277-014-1978-x↗
  38. Comment on Han L et al.: prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Last author DOI 10.1007/s13277-014-2507-7↗
  39. Association of c.461G>A genetic variant of OGG1 gene with pancreatic cancer susceptibility in Chinese. Last author DOI 10.4238/2014.september.5.10↗
  40. Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients. Last author PMID 25120791↗
  41. Complications after pancreaticoduodenectomy for pancreatic cancer: a retrospective study. Co-author DOI 10.9738/cc17.1↗

Trials 1

  1. Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Principal investigator NCT02135822↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiming Zhao · 16 shared papers, 2014–2026 · strength 2.49
  2. Xiuping Zhang · 8 shared papers, 2021–2026 · strength 1.58
  3. Wenbo Zou · 7 shared papers, 2021–2025 · strength 1.35
  4. Minggen Hu · 8 shared papers, 2015–2023 · strength 1.15
  5. Lincheng Li · 6 shared papers, 2021–2023 · strength 1.12
  6. Zhaoda Deng · 5 shared papers, 2022–2023 · strength 0.97
  7. Qu Liu · 5 shared papers, 2021–2023 · strength 0.81
  8. Zhiming Zhao · 5 shared papers, 2014–2023 · strength 0.67
  9. Shuai Xu · 3 shared papers, 2022–2025 · strength 0.56
  10. Shuai Xu · 3 shared papers, 2022–2023 · strength 0.55
  11. Fei Wang · 3 shared papers, 2021–2023 · strength 0.53
  12. Gong Zhang · 3 shared papers, 2021–2023 · strength 0.50
  13. Peizi Liu · 2 shared papers, 2025–2026 · strength 0.48
  14. Zizheng Wang · 3 shared papers, 2021–2023 · strength 0.47
  15. Wan Yee Lau · 3 shared papers, 2021–2023 · strength 0.46
  16. Hailiang Liu · 3 shared papers, 2015–2021 · strength 0.41
  17. Tan X · 2 shared papers, 2020–2021 · strength 0.33
  18. Ye Xu · 1 shared paper, 2025 · strength 0.33
  19. Chenggang Li · 4 shared papers, 2014–2020 · strength 0.32
  20. Chenggang Li · 2 shared papers, 2016–2022 · strength 0.31
  21. Xianjun Yu · 2 shared papers, 2023–2025 · strength 0.31
  22. Chen Liu · 2 shared papers, 2023–2025 · strength 0.31
  23. Xiaowu Xu · 2 shared papers, 2023–2025 · strength 0.31
  24. Renyi Qin · 2 shared papers, 2023–2025 · strength 0.31
  25. Shunrong Ji · 2 shared papers, 2023–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.